PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2010 May 27.
Published in final edited form as:
PMCID: PMC2877371
NIHMSID: NIHMS194014

Membrane Type 1 Matrix Metalloproteinase Mediated Stromal Syndecan-1 Shedding Stimulates Breast Carcinoma Cell Proliferation

Abstract

Mounting evidence implicates stromal fibroblasts in breast carcinoma progression. We have recently shown in 3D co-culture experiments that human mammary fibroblasts stimulate the proliferation of T47D breast carcinoma cells and that this activity requires the shedding of the heparan sulfate proteoglycan syndecan-1 from the fibroblast surface. The goal of this project was to determine the mechanism of syndecan-1 ectodomain shedding. The broad-spectrum matrix metalloproteinase (MMP) inhibitor GM6001 specifically blocked syndecan-1-mediated carcinoma cell growth stimulation, pointing toward MMPs as critical enzymes involved in syndecan-1 shedding. MMP-2 and membrane type 1 MMP (MT1-MMP) were the predominant MMPs expressed by the mammary fibroblasts. Fibroblast-dependent carcinoma cell growth stimulation in 3D co-culture was abolished by MT1-MMP expression silencing with siRNA and restored either by adding recombinant MT1-MMP catalytic domain or by expressing a secreted form of syndecan-1 in the fibroblasts. These findings are consistent with a model where fibroblast-derived MT1-MMP cleaves syndecan-1 at the fibroblast surface, leading to paracrine growth stimulation of carcinoma cells by syndecan-1 ectodomain. The relevance of MT1-MMP in paracrine interactions was further supported by co-culture experiments with T47D cells and primary fibroblasts isolated from human breast carcinomas or matched normal breast tissue. Carcinoma associated fibroblasts stimulated T47D cell proliferation significantly more than normal fibroblasts in 3D co-culture. Function-blocking anti-MT1-MMP antibody significantly inhibited the T47D cell growth stimulation in co-culture with primary fibroblasts. In summary, these results ascribe a novel role to fibroblast-derived MT1-MMP in stromal-epithelial signaling in breast carcinomas.

Keywords: breast neoplasms, tumor stroma, fibroblasts, proteoglycans, matrix metalloproteinase

Introduction

The importance of the stroma in cancer development and progression is being increasingly recognized. Stromal fibroblasts participate in reciprocal interactions with carcinoma cells, which modulate carcinoma cell proliferation (1). The cell surface proteoglycan syndecan-1 (Sdc1), which in adult tissues is expressed mainly in epithelial and plasma cells, is induced in breast carcinoma stromal fibroblasts, recapitulating the stromal expression seen during mammary morphogenesis (2, 3). We have shown that stromal Sdc1 stimulates breast carcinoma cell proliferation in vitro and in vivo (3, 4). Recent work from our group has shed light on the mechanisms of stromal Sdc1-dependent growth stimulation (5). The induction of carcinoma cell proliferation in collagen gels requires the proteolytic release of the Sdc1 ectodomain, effectively converting the proteoglycan cell surface receptor into a diffusible, paracrine mediator. The growth promoting activity requires the heparan sulfate (HS) chains and the presence of stromal cell-derived factor 1 (SDF1) and fibroblast growth factor 2 (FGF2). This finding suggests that HS from the Sdc1 ectodomain either stabilizes these growth factors in the 3D co-culture environment or more likely participates in a ternary complex with ligands and signaling receptors. Sdc1 shedding has been shown to regulate a multitude of biologic functions in a cell-autonomous and non-autonomous fashion (68). Apart from mediating the matrix and growth factor co-receptor functions of cell membrane anchored Sdc1, the Sdc1 ectodomain appears to have some unique roles in biologic events. Soluble Sdc1, which forms a complex with chemokines, is required to create chemotactic gradients in a model of lung inflammation (7). Shed Sdc1 modifies the tumor microenvironment and promotes tumor progression and metastasis in myelomas (9). Cleavage of Sdc1 by MT1-MMP stimulates HT1080 fibrosarcoma cell migration (8). Elevated amounts of Sdc1 shedding in the blood stream indicate an ominous prognosis in several malignancies (10, 11).

Sdc1 is released constitutively from the cell surface and shedding is enhanced in response to a number of different stimuli, such as treatment with SDF1 or HS degradation with heparanase (12, 13). The identity of the enzyme(s) responsible for Sdc1 cleavage and release of the ectodomain has been the topic of some debate. There is a general consensus that members of the metalloproteinase (MMP) family mediate Sdc1 cleavage. A TIMP-3 sensitive metalloproteinase (14), a non-matrix metalloproteinase (15), MMP-7 (7, 16), MMP-9 (12) and MT1-MMP (8, 17) have all been implicated in Sdc1 shedding. It is unclear whether these enzymes constitute alternative direct Sdc1 cleavage mechanisms or whether some of them promote shedding indirectly.

The goal of this study was to investigate the mechanism of Sdc1 shedding in our 3D collagen gel co-culture system. We found that MT1-MMP expressed by stromal fibroblasts directly cleaves Sdc1 at the surface of the same cell type and thus releases Sdc1 ectodomain as a paracrine mediator. Sdc1 ectodomain stimulates breast carcinoma cell proliferation as we have previously shown. This finding demonstrates a novel, pro-tumorigenic role for MT1-MMP in breast cancer.

Materials and Methods

Antibodies and reagents

Mouse anti-human MMP-2 monoclonal antibody was purchased from Chemicon International (Billerica, MA). Rabbit polyclonal antibody against MT1-MMP hinge region and rabbit anti-MT1-MMP catalytic domain polyclonal antibody were from Abcam (Cambridge, MA). Mouse anti-human mucin-1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-human pan-keratin mouse monoclonal antibody was from Lab Vision (Fremont, CA). Rat monoclonal antibody (clone 281.2) directed against mouse syndecan-1 extracellular domain and rabbit polyclonal antibody against syndecan cytoplasmic domain (S1CD) were kindly provided by Dr. A. C. Rapraeger (University of Wisconsin-Madison). Type I rat tail collagen was purchased from BD Biosciences (Bedford, MA). Human recombinant MT1-MMP catalytic domain, MMP-2 inhibitor III and GM 6001 MMP inhibitor were from Calbiochem (San Diego, CA). Recombinant human MMP-2 was from R & D Systems Inc. (Minneapolis, MN). Collagenase I and hyaluronidase were purchased from Sigma (St. Louis, MO).

Cell culture

The human breast carcinoma cell line T47D was obtained from Dr. M. Gould (University of Wisconsin-Madison). Normal mammary fibroblasts immortalized with human telomerase and GFP-labeled were generously provided by Dr. C. Kuperwasser (18). These cells were originally named RMF/EG and are referred to as human mammary fibroblasts (HMF) throughout this paper. T47D cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, and penicillin/streptomycin (100U/ml). HMF cells were cultured in DMEM supplemented with 10% calf serum (CS), 2mM L-glutamine, and penicillin/streptomycin (100U/ml). All cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2.

Collagen gel co-culture and cell growth assay

Three-dimensional collagen gel co-culture was established as previously described (5). Briefly, T47D cells and HMF cells were mixed at a ratio of 2:1 in collagen type I gel at a final collagen concentration of 1.3mg/ml. T47D growth was quantified as pixel area of mucin-1 staining. Anti-mucin-1 antibody specifically stains T47D cells. The collagen gel was fixed and stained with rabbit anti human mucin-1. Images were acquired using a SPOT imaging system (Diagnostic Instruments, Inc., Sterling Heights, MI) on an Olympus inverted microscope. The mucin-1-positive area was measured using Image J software (http://rsb.info.nih.gov/ij/).

Quantitative RT-PCR

Quantitative Real-Time PCR (qRT-PCR) was performed to measure MMP mRNA levels. Cells were dissociated from the collagen gel by collagenase and enzyme-free cell dissociation buffer. HMF and T47D cells were sorted with a triple-laser FACSVantage SE flow cytometer equipped with FACSDiva software. Then, total RNA was isolated from the two cell populations using the RNeasy Mini Kit (Qiagen, CA). Cell number equivalents of total RNA from T47D or HMF cells were reverse transcribed into cDNA using the ThermoScript™ RT-PCR System (Invitrogen, Carlsbad, CA). Primers were purchased from SuperArray Bioscience (Frederick, MD). Five percent of the reverse transcription product was used in the qRT-PCR reaction with SYBR Green PCR master mix on an iCycler instrument (Bio-Rad, Hercules, CA). GAPDH mRNA was used as a reference.

siRNA transfection

MT1-MMP siRNA oligonucleotides were purchased from Ambion (Austin, TX). Five µg of siRNA oligonucleotides were delivered to 5 × 105 HMF using the Basic Nucleofector Kit for primary mammalian fibroblasts and the Nucleofector device (Amaxa Biosystem, Gaithersburg, MD) according to the manufacturer’s protocol. After 48–72 hours post transfection, the HMF cells were lifted in trypsin (0.25% wt/vol) and co-cultured with T47D cells in collagen gels. MT1-MMP siRNA oligonucleotides were validated by qRT-PCR and Western blot.

Gel electrophoresis and Western blotting

Cells were lysed in RIPA buffer (Boston Bioproducts, Worcester, MA) containing protease inhibitor cocktail (Pierce, Rockford, IL) for 30 minutes on ice. The cell lysates were centrifuged at 10,000 rpm. The supernatants were collected and protein concentration was measured. Samples and pre-stained molecular mass markers (Bio-Rad) were denatured in sample buffer (SDS 2%, glycerol 10%, bromophenol blue, β-mercaptoethanol 2.5%) and heated to 100°C for 1 minute before gel electrophoresis. Samples were then electrophoretically separated on Criterion™ XT precast gels (Bio-Rad) and transferred to a polyvinylidene diflouride membrane (PVDF). The blots were probed with anti MT1-MMP antibody (1µg/ml). A horseradish peroxidase-conjugated secondary IgG (Sigma) was used for detection. The signal was visualized with SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL).

Syndecan-1 shedding assay

HMFs overexpressing mouse Sdc1 (mSdc1; cells generated in our laboratory by Dr. Ning Yang) were cultured to 90% confluence. Culture media was replaced with Hank’s Balanced Salt Solution (HBSS). Cells were treated with recombinant MT1-MMP catalytic domain at concentrations of 0 or 500 ng/ml at 37 °C for one hour in the presence or absence of 2.5µM GM6001. The supernatant was then collected and diluted with one volume of TUT buffer (Tris 10mM, urea 8M, Triton X-100 0.1%, Na2SO4 1mM, PMSF 1mM, N-ethylmaleimide 1mM, pH 8.0). Then, 100 µl of DEAE beads pre-equilibrated with TUT were added. Tubes containing DEAE beads and media were rotated overnight at 4°C. Sdc1 was eluted with high salt HEPES buffer (30mM HEPES, 1M NaCl, pH 7.4). After the salt was removed with a desalting column (Pierce, Rockford, IL), the sample was digested with heparitinase and chondroitinase ABC (0.002 U/ml) twice for two hours to remove all glycosaminoglycan chains and analyzed by Western blot.

Flow cytometry

HMFs overexpressing mSdc1 were cultured to 90% confluence. Cells were lifted with enzyme free cell dissociation buffer (Life Technologies, Inc.-Invitrogen Corp., Grand Island, NY) and washed twice with Hank’s Balanced Salt Solution (HBSS). The cells (0.5 × 106) were subsequently resuspended in HBSS and treated with 1µg rMT1-MMP at 37 °C for one hour. In the control samples, the enzyme was either omitted or the MMP inhibitor GM6001 was added at 2.5 µM. HMF cells were then collected and incubated with 5µg rat monoclonal antibody (clone 281.2) directed against mSdc1 extracellular domain at 4 °C for one hour in FACS buffer (2% FBS in PBS). After three washes with FACS buffer, HMF cells were incubated with goat anti-rat IgG conjugated with R-phycoerythrin at 4 °C for one hour. After washing, the samples were analyzed on a FACS Caliber bench top cytometer (BD Biosciences). Cell scatter and propidium iodide (Sigma-Aldrich, 1µg/sample) staining profiles were used to gate live, single-cell events for data analysis.

HA tagged mouse syndecan-1 in vitro digestion assay

An expression plasmid for amino terminal HA tagged mSdc1 (HA-mSdc1, generated in our laboratory by Dr. Dianhua Qiao) was transfected into 293A cells and 48 hours later, the cells were lysed in RIPA buffer (NP-40 1%, Sodium deoxycholate 0.5%, SDS 0.1%, NaCl 150mM, EDTA 5mM, Tris-HCl 50mM pH 7.4). The cell lysate (500µg protein) was incubated with 50µl anti-HA affinity beads (Roche Applied Science, Mannheim, Germany) at 4 °C overnight. The beads were washed and treated with 0µg or 1µg rMT1-MMP with or without 2.5µM of GM6001, or with 1µg rMMP-2 in hydrolysis buffer (NaCl 150mM, Tris-HCl 50mM, CaCl2 5mM, Brij 35 0.025%, pH 7.5) at 37 °C for one hour. Then the beads were boiled in sample buffer for 5 minutes and the supernatant was electrophoretically separated on 12% Bis-Tris Criterion XT precast gels (Bio-Rad). The gel was either silver-stained, or transferred to a polyvinylidene diflouride membrane (PVDF) for probing with rabbit polyclonal antibody against syndecan cytoplasmic domain (S1CD).

Primary breast fibroblast culture

The use of human tissue was approved by the institutional review board. Human breast tissue was minced into 1–2 mm pieces and subsequently digested with collagenase I (2mg/ml) and hyaluronidase (2mg/ml) in DMEM for two hours at 37°C. Digested tissue was spun down at 3,000 rpm for 5 minutes and washed with HBSS. For normal tissue, the digested tissue was re-suspended in HBSS, and filtered through 100µm and 40µm cell strainers (BD Bioscience, Bedford, MA). The flow-through was collected, the cells were harvested by centrifugation (3000 rpm, 5 minutes), and seeded in tissue culture plates in complete DMEM containing 10% FBS, 2mM L-glutamine, and penicillin/streptomycin (100U/ml). Breast tumor tissue was further digested in 0.25% trypsin at 37°C for 10 minutes. Then, the digested tumor tissue was processed in the same manner as normal breast tissue. The cells were collected and seeded in tissue culture plates. The next day, dead cells, unattached cells, and tissue debris were removed. Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2. The epithelial cell contamination in primary fibroblast cultures was estimated as the percentage of cells displaying positive mucin-1 or cytokeratin staining. Because the culture media favors fibroblast cell growth, confluent primary fibroblast cultures contain less then 1% of epithelial cell contamination.

Immunofluorescence staining

Cells growing on chamber slides were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature and washed for 20 minutes in PBS. Cells were then treated with 0.15 M glycine in PBS for 30 minutes to reduce autofluorescence. After washing with PBS for 20 minutes, cells were permeabilized with 0.5 % Triton X-100 in PBS for 15 minutes and blocked with 10% goat serum in PBS for 1 hour at room temperature. Cells were then incubated with primary antibody at room temperature for 1.5 hours. After extensive washing with PBS, the secondary antibody was added for 1 hour at room temperature. Immunostaining was then analyzed with a fluorescence microscope.

Results

T47D mammary carcinoma cell growth stimulation by fibroblasts requires MMP activity

Human mammary fibroblasts (HMF) stimulate growth of T47D mammary carcinoma cells in 3D co-culture – an activity that requires the induction of Sdc1 expression in the fibroblasts and the proteolytic release of this proteoglycan from the fibroblast surface (5). A number of different enzymes have been implicated in Sdc1 shedding, all of which belong to the MMP family (7, 8, 12, 16, 17). Therefore, one would predict that the inhibition of Sdc1 cleavage with a MMP inhibitor would abolish fibroblast-mediated carcinoma growth stimulation. Indeed, when GM6001, a broad-spectrum MMP inhibitor, is added to the co-cultures, T47D cell growth is inhibited in a dose dependent manner while T47D monoculture growth is unaffected (Fig. 1A). This result indicates that MMP activity is required for HMF-mediated T47D cell growth stimulation.

Figure 1
GM6001 inhibits T47D growth stimulation in co-culture; MMP-2 and MT1-MMP mRNA levels are altered by co-culture

HMF-derived MMP-2 and MT1-MMP are the most abundant MMPs in T47D/HMF co-culture

MMP-2, MMP-7, MMP-9, MMP-11, MMP-13, and MT1-MMP are the MMP family members that have been implicated in breast cancer progression (19, 20). Therefore, we analyzed mRNA levels of these MMPs in HMF and T47D cells. T47D cells produce extremely low mRNA levels for each of these MMPs (Table 1). This finding is consistent with reports by other investigators that poorly invasive breast cancer cells such as T47D or MCF7 do not express MMPs at significant levels (21). In HMF cells, MMP-2 and MT1-MMP were the predominant MMPs (Table 1). Since MMP expression in stromal fibroblast can be modulated by carcinoma cells (2224), we compared expression levels in mono- and co-culture. We discovered that the MMP-2 mRNA level in HMF is decreased under co-culture conditions. In contrast, the fibroblast MT1-MMP mRNA level is significantly increased during co-culture (Fig. 1B). In T47D cells, both MMP-2 and MT1-MMP mRNA levels remain low during co-culture, although the MMP-2 level is significantly increased in co-culture compared to monoculture (Fig. 1C).

Table 1
MMP mRNA levels in HMF or T47D cells relative to GAPDH

MT1-MMP expression in HMF cells is required for T47D carcinoma cell growth stimulation

Next, we tested whether MMP-2, MT1-MMP, or both are required for T47D growth stimulation in collagen gel co-culture. Neither the small molecule MMP-2 inhibitor III (2-((Isopropoxy)-(1,1'-biphenyl-4-ylsulfonyl)-amino))-N-hydroxyacetamide nor neutralizing anti-MMP-2 antibody suppress T47D cell growth in monoculture or co-culture (Fig. S1). Conversely, when MT1-MMP is inhibited by adding a neutralizing antibody directed against the MT1-MMP catalytic domain, T47D cell growth in co-culture is reduced to the level of monoculture (Fig. 2A). The neutralizing activity of the anti-MMP-2 and anti-MT1-MMP antibodies was validated with an in vitro fluorogenic substrate digestion assay (Fig. S2).

Figure 2
Inhibition of MT1-MMP blocks T47D cell growth stimulation in co-culture

To further ascertain the importance of fibroblast MT1-MMP for carcinoma cell growth stimulation, we knocked down expression of this enzyme in fibroblasts with siRNA. Prior to mixing the two cell types for the co-culture experiments, HMF cells were transiently transfected with MT1-MMP siRNA or control siRNA oligonucleotides. The efficacy of the MT1-MMP siRNA treatment was validated by both quantitative RT-PCR and immunoblot analysis. MT1-MMP siRNA reduces the mRNA level by almost 80% (Fig. 2B) and decreases the protein level considerably (Fig. 2C). The siRNA treatment of HMF cells reduces the growth stimulation of T47D cells to the level of T47D cell growth in monoculture, whereas control siRNA has no effect (Fig. 2D). Importantly, the addition of recombinant MT1-MMP catalytic domain (rMT1-MMP) to the co-culture completely restores T47D growth stimulation to the control level (Fig. 2D). These results indicate that fibroblast-derived MT1-MMP is required for T47D cell growth stimulation in co-culture and that soluble enzyme can substitute for endogenous, membrane-bound MT1- MMP.

Secreted Sdc1 ectodomain bypasses the requirement for MT1-MMP activity in coculture

We hypothesize that fibroblast MT1-MMP stimulates T47D carcinoma cell growth indirectly by cleaving and releasing Sdc1. If this model is correct, one would anticipate that adding Sdc1 ectodomain to the co-culture should reverse the T47D cell growth inhibition caused by blocking fibroblast MT1-MMP activity. To test this hypothesis, we forcibly expressed a soluble, secreted form of mouse Sdc1 in HMF (25) in co-culture with T47D cells. Soluble Sdc1 expressed in HMF completely restores the T47D cell growth stimulation in the presence of the MMP inhibitor GM6001 (Fig. 3A). Similarly, T47D cell growth inhibition in response to MT1-MMP neutralizing antibody treatment or as a result of MT1-MMP siRNA knock-down in fibroblasts is entirely reversed by the expression of soluble Sdc1 in HMF (Fig. 3B, C). These data suggest that in this co-culture model, MT1-MMP stimulates carcinoma cell growth primarily by releasing Sdc1 ectodomain as a paracrine mediator from the fibroblast surface.

Figure 3
Soluble mSdc1 restores T47D cell growth stimulation in co-culture when MT1-MMP activity is inhibited

Sdc1 is a MT1-MMP substrate

To verify that MT1-MMP participates in Sdc1 shedding, we applied rMT1-MMP to monolayers of mSdc1-overexpressing HMF. The activity of rMT1-MMP was confirmed with fluorogenic substrate (data not shown). mSdc1 was detected in the media after the cells were exposed to rMT1-MMP, whereas mSdc1 was absent from the media in the presence of the MMP inhibitor GM6001 (Fig. 4A). Most of the shed mSdc1 is detected as an apparent SDS-resistant dimer, migrating at approximately 150 kDa, which is consistent with reports by other investigators (26). To further demonstrate that MT1-MMP induces Sdc1 shedding, we performed flow cytometric analysis of cell surface mSdc1 with and without rMT1-MMP exposure. rMT1-MMP treatment decreases the level of cell surface mSdc1 by approximately two-thirds, although a significant amount of mSdc1 remains on the cell surface (Fig. 4B). The MMP inhibitor GM6001 reverses this decrease. This result indicates that MT1-MMP promotes Sdc1 shedding from the surface of stromal fibroblasts but is not definitive evidence for direct proteolytic cleavage of Sdc1 by MT1-MMP. One possibility is that MMP-2, or some other enzyme which is also present in the co-cultures, is activated by MT1-MMP and that this activated enzyme then cleaves Sdc1. However, such an indirect mechanism of Sdc1 release by MMP-2 is unlikely given that MMP-2 inhibition had no effect on fibroblast-mediated growth stimulation of T47D carcinoma cells (Fig. S1).

Figure 4
Recombinant MT1-MMP induces Sdc1 shedding and cleaves Sdc1 in vitro

To demonstrate directly that mSdc1 is a substrate of MT1-MMP, we performed a digestion assay with isolated HA-tagged mSdc1 (HA-mSdc1) in vitro. HA-mSdc1 was produced in 293A cells and enriched with anti-HA affinity beads. After exposure to rMT1-MMP or active rMMP-2, digested HA-mSdc1 was analyzed by silver-staining and Western blot. Intact HA-mSdc1 migrates by SDS-PAGE consistent with its molecular weight of approximately 40 kDa (Fig. 4C, D), contrasting with the anomalous slow migration typically observed with wild-type Sdc1 (5, 27). In our experiments, the HA sequence may interfere with the “extended” conformations thought to be responsible for the anomalous migration of Sdc1 (27). A fragment of approximately 25 kDa is also seen in all samples containing HA-mSdc1. This fragment is not modified by the addition of rMT1-MMP or rMMP-2 (Fig. 4C) and does not react with antibody directed against the cytoplasmic domain of mSdc1 (Fig. 4D), and therefore, is likely nonspecific.

Since MT1-MMP has been reported to cleave mSdc1 at a juxtamembrane site (Ala243-Ser244) (28), one predicts that after MT1-MMP treatment, a small fragment containing transmembrane and cytoplasmic domains of mSdc1 with a size of approximately 10 kDa would appear. Indeed, after incubation with rMT1-MMP, bands corresponding to fragments of about 30 and 10 kDa replace full length HA-mSdc1 in the silver-stained gel (lane 3 in Fig. 4C). Conversely, when incubated with activated rMMP-2, full length HA-mSdc1 remains at a high level, although bands of approximately 30 kDa appear (lane 5 in Fig. 4C). No short peptide corresponding to a fragment containing the transmembrane and cytoplasmic domains of mSdc1 is detected. This suggests that rMMP-2 does not cleave HA-mSdc1 at the juxtamembrane site, but instead might cleave HA-mSdc1 at a different site located closer to the amino-terminus.

To verify that the small fragment generated by rMT1-MMP digestion contains the cytoplasmic domain of mSdc1, we probed the membrane with a rabbit polyclonal antibody (S1CD) directed against this molecular region (Fig. 4D). Indeed, the small fragment with a size of approximately 10 kDa reacts with the anti-cytoplasmic domain antibody. Interestingly, a larger ~30 kDa fragment is also recognized by this antibody, suggesting that mSdc1 contains another MT1-MMP-sensitive cleavage site closer to the amino-terminus. As a matter of fact, Endo and co-workers localized a MT1-MMP-sensitive site at Gly82-Leu83 in human Sdc1 (8). The S1CD antibody also reacts with a ~30 kDa sized fragment generated by rMMP-2, however, consistent with the silver staining result, a smaller ~10 kDa fragment is not detected. This further supports our conclusion that rMMP-2 does not cleave mSdc1 at the juxtamembrane site.

Primary cancer associated fibroblasts stimulate T47D cell growth significantly more than normal fibroblasts in a MT1-MMP activity dependent manner

To evaluate the relevance of stroma cell-derived MT1-MMP in human breast cancer, we isolated stromal fibroblasts from both human breast carcinoma tissue (CAF) and matched adjacent normal breast tissue (NF) and compared their interaction with T47D cells in collagen gel matrix co-culture. Twelve pairs of CAF and NF, each derived from a different patient, were tested in co-culture. The samples included 10 infiltrating ductal carcinomas, one mucinous carcinoma and one infiltrating lobular carcinoma. To test the purity of the isolated cells, we stained with antibodies to the fibroblast marker S100A4/FSP1 and the myofibroblast marker smooth muscle actin (SMA). Both CAF and NF were uniformly positive for S100A4/FSP1 and a subset of cells from either source also expressed SMA (Fig. 5A). When CAF or NF were co-cultured with T47D cells in collagen gel matrix, CAF stimulated T47D proliferation to a significantly greater extent than NF (Fig. 5B). Neutralizing anti-MT1-MMP antibody abolishes the growth advantage induced by CAF over NF (Fig. 5B), indicating that in primary human breast carcinomas, fibroblasts produce MT1-MMP with a carcinoma growth promoting activity.

Figure 5
CAF stimulate T47D carcinoma cell proliferation significantly more than NF and inhibition of MT1-MMP reverses this growth advantage

Discussion

MT1-MMP is expressed in both breast carcinoma cells and peritumor stromal fibroblasts (2932) and has been implicated in breast carcinoma progression. Most mechanistic work has focused on MT1-MMP expressed by carcinoma cells and has established roles in invasion, growth and metastasis. The role of stroma cell-derived MT1-MMP in cancer progression is less well known. In the present study, we found that MT1-MMP from stromal fibroblast is responsible for the shedding of stromal Sdc1, which subsequently stimulates breast carcinoma cell proliferation in three dimensional collagen gel co-culture.

MT1-MMP expression is regulated by cell-autonomous and microenvironmental mechanisms. In mammary carcinoma cells, MT1-MMP levels are under the control of the transcriptional modulator Id-1 and zonula occludens protein 1 (ZO-1). Contact with collagen 1 and hypoxic conditions stimulate MT1-MMP expression (33, 34). Interestingly, myoepithelial cells, which are physiologically located between mammary epithelial cells and the surrounding stroma, reduce MT1-MMP expression (35). Conditioned medium from the highly aggressive MDA-MB-231, but not the less aggressive MCF-7 breast carcinoma cells, stimulates MT1-MMP expression in human fibroblasts, suggesting an induction by secreted factors (22). Conversely, Selvey and co-workers were unable to detect MT1-MMP induction in fibroblasts during non-contact co-culture with breast carcinoma cells (23). We observed a significant induction of fibroblast MT1-MMP mRNA levels in direct co-culture with well-differentiated T47D breast carcinoma cells (Fig. 1B). In vivo, high-level stromal MT1-MMP expression is limited to fibroblasts in the immediate vicinity of tumor islands, suggesting that either direct tumor cell contact or a short-range or labile paracrine factor mediates the induction (32).

MT1-MMP stimulates cancer growth and invasion by a variety of direct and indirect mechanisms. One of the recognized cardinal functions of MT1-MMP is the activation of other proteases, particularly MMP-2. In an elegant xenograft study, Taniwaki and colleagues showed that carcinoma cell growth stimulation by MT1-MMP depended on the stromal supply of MMP-2 (36). Conversely, Hotary demonstrated that MT1-MMP-stimulated carcinoma cell growth in 3D collagen matrices did not require MMP-2 or other proteases of the MMP family (37). Similarly, in our study, MMP-2 inhibition with a neutralizing antibody or a small molecule inhibitor had no effect on carcinoma cell growth stimulation by fibroblasts, arguing against a role of this enzyme in our model.

MT1-MMP can stimulate carcinoma cell invasion and proliferation directly by collagen degradation (3739). In Hotary’s work, MT1-MMP-mediated carcinoma cell growth was abolished when the cells were embedded in mutant, protease-resistant collagen (37). Despite the fact that T47D cells were suspended in collagen in our study, it is unlikely that collagen degradation played a role in fibroblast-induced carcinoma cell growth stimulation. The effect of MT1-MMP inhibition on carcinoma cell growth was reversed by the addition of Sdc1 ectodomain indicating that Sdc1 cleavage was the only required MT1-MMP activity (Fig. 3). Also, in contrast to the work by Hotary which showed that accelerated growth required anchorage of the enzyme at the cell surface (37), soluble MT1-MMP catalytic domain was sufficient to restore growth in our study (Fig. 2D). Thus, it appears that the prevailing MT1-MMP mechanism of action depends on cell source and target cell type. For instance, MT1-MMP on tumor cells cleaves cell surface molecules, such as integrins, to facilitate cell adhesion and migration (40, 41). Stromal cell-derived MT1-MMP may contribute to tumor growth and invasion indirectly by releasing paracrine mediators from the pericellular environment. These diverse functions of MT1-MMP are facilitated by a surprisingly wide spectrum of substrates (42). A recent proteomics study identified a number of cell surface extra cellular matrix (ECM) constituents, receptors and cytokines as MT1-MMP substrates (43).

A variety of enzymes have been implicated in Sdc1 shedding. These include a TIMP-3-sensitive unidentified MMP (14), MMP-7 (7, 16) and MMP-9 (12). The most conclusive evidence for a direct enzymatic degradation of Sdc1 has been presented for MT1-MMP (8). The MT1-MMP consensus cleavage site contains the amino acid sequence PXX ↓L (ideally PXP↓L or PXG↓L) (44). P80TG↓L83 represents the only such consensus site in human Sdc1 (hSdc1). However, MT1-MMP has also been found to cleave hSdc1 at S243QG↓L246, an alternative site not conforming with the consensus sequence (44). MT1-MMP cleaves mSdc1 at A243↓SQSL247, another site sharing no similarity with the consensus sequence described above (44). According to its amino acid sequence, mSdc1 contains a MT1-MMP consensus cleavage site at P53DT↓L56 and our results suggest that MT1-MMP indeed cleaves mSdc1 at this location. Our in vitro digestion results indicate that MMP-2 is not involved in Sdc1 shedding although the enzyme displays some digestive activity towards the amino-terminal portion of HA-mSdc1.

The evidence presented here and in recent reports by our group suggests a complex, reciprocal interplay between breast carcinoma cells and stromal fibroblasts, involving the induction of Sdc1 and MT1-MMP expression in fibroblasts by carcinoma cells followed by MT1-MMP-mediated shedding of Sdc1 ectodomain from the fibroblast surface (35). The HS chains attached to the released Sdc1 ectodomain fragments stimulate breast carcinoma cell proliferation by augmenting SDF1 and FGF2 activity (5).

Since this model was devised using an assay system with an immortalized mammary fibroblast cell line, the question can be raised how relevant the described pathways are in human breast cancer. Our observations on co-cultures of primary fibroblasts with T47D breast carcinoma cells suggest that stromal MT1-MMP plays a role in the majority of breast carcinomas (Fig. 5B). Consistent with reports by other investigators (45), CAFs stimulate carcinoma cells to a greater degree than NFs. Apparently, the differences between CAFs and NFs were maintained during the brief culture period, despite the fact that some NFs in culture displayed an activated, myofibroblast-like, SMA-positive phenotype (Fig. 5A). Surprisingly, NFs show a more pronounced heterogeneity than CAFs as far as their carcinoma cell growth-promoting capability is concerned (Fig. 5B). The inactivation of MT1-MMP activity with a neutralizing antibody significantly reduced carcinoma cell growth stimulation by CAFs.

Broad spectrum MMP inhibitors have been a disappointment in clinical trials (46). One reason for this failure could be the fact that MMPs may have dual roles in tumor promotion and suppression (20, 46). MMPs release anti-angiogenic peptides such as endostatin, angiostatin or endorepellin from their ECM precursor molecules. Therefore, the unselective inhibition of all MMPs may have either a neutral or even adverse effect on disease outcome. A specific blockage of MT1-MMP appears a promising therapeutic strategy to inhibit both breast carcinoma cell invasion and disrupt the novel paracrine, growth promoting signaling pathway described here.

Acknowledgments

Financial Support/Acknowledgements

The authors would like to thank the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC) Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, & Pharmacogenetics (3P Lab) for RT-PCR support. This research was supported by a grant from the National Institutes of Health (R01CA107012-01A1). We are grateful to Dr. Ralph Sanderson for providing several syndecan mutant cDNAs as detailed in Materials and Methods. We thank Dr. Korise Rasmusson for help with manuscript preparation.

References

1. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401. [PubMed]
2. Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol. 1999;112:377–383. [PubMed]
3. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004;64:612–621. [PubMed]
4. Maeda T, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene. 2006;25:1408–1412. [PubMed]
5. Su G, Blaine SA, Qiao D, Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem. 2007;282:14906–14915. [PubMed]
6. Elenius V, Gotte M, Reizes O, Elenius K, Bernfield M. Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem. 2004;279:41928–41935. [PubMed]
7. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111:635–646. [PubMed]
8. Endo K, Takino T, Miyamori H, et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem. 2003;278:40764–40770. [PubMed]
9. Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2007
10. Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002;62:5210–5217. [PubMed]
11. Lovell R, Dunn JA, Begum G, et al. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol. 2005;130:542–548. [PubMed]
12. Brule S, Charnaux N, Sutton A, et al. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology. 2006;16:488–501. [PubMed]
13. Yang Y, Macleod V, Miao HQ, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007;282:13326–13333. [PubMed]
14. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol. 2000;148:811–824. [PMC free article] [PubMed]
15. Holen I, Drury NL, Hargreaves PG, Croucher PI. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol. 2001;114:414–421. [PubMed]
16. Ding K, Lopez-Burks M, Sanchez-Duran JA, Korc M, Lander AD. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol. 2005;171:729–738. [PMC free article] [PubMed]
17. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci. 2007;98:563–568. [PubMed]
18. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A. 2004;101:4966–4971. [PubMed]
19. Rudolph-Owen LA, Matrisian LM. Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. J Mammary Gland Biol Neoplasia. 1998;3:177–189. [PubMed]
20. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–239. [PubMed]
21. Pulyaeva H, Bueno J, Polette M, et al. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis. 1997;15:111–120. [PubMed]
22. Polette M, Gilles C, Marchand V, Seiki M, Tournier JM, Birembaut P. Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis. 1997;15:157–163. [PubMed]
23. Selvey S, Haupt LM, Thompson EW, Matthaei KI, Irving MG, Griffiths LR. Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines. BMC Cancer. 2004;4:40. [PMC free article] [PubMed]
24. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 2004;92:47–56. [PubMed]
25. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002;100:610–617. [PubMed]
26. Miettinen HM, Edwards SN, Jalkanen M. Analysis of transport and targeting of syndecan-1: effect of cytoplasmic tail deletions. Mol Biol Cell. 1994;5:1325–1339. [PMC free article] [PubMed]
27. Saunders S, Jalkanen M, O'Farrell S, Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol. 1989;108:1547–1556. [PMC free article] [PubMed]
28. Wang Z, Gotte M, Bernfield M, Reizes O. Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry. 2005;44:12355–12361. [PMC free article] [PubMed]
29. Haupt LM, Irving RE, Weinstein SR, Irving MG, Griffiths LR. Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material. Mol Cell Probesc. 2008;22:83–89. [PubMed]
30. Mylona E, Nomikos A, Magkou C, et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology. 2007;50:338–347. [PubMed]
31. Chenard MP, Lutz Y, Mechine-Neuville A, et al. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas. Int J Cancer. 1999;82:208–212. [PubMed]
32. Bisson C, Blacher S, Polette M, et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer. 2003;105:7–13. [PubMed]
33. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 2006;25:2379–2392. [PubMed]
34. Borrirukwanit K, Lafleur MA, Mercuri FA, et al. The type I collagen induction of MT1-MMP-mediated MMP-2 activation is repressed by alphaVbeta3 integrin in human breast cancer cells. Matrix Biol. 2007;26:291–305. [PubMed]
35. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol. 2003;201:562–572. [PubMed]
36. Taniwaki K, Fukamachi H, Komori K, et al. Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res. 2007;67:4311–4319. [PubMed]
37. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003;114:33–45. [PubMed]
38. Lee H, Sodek KL, Hwang Q, Brown TJ, Ringuette M, Sodek J. Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem Soc Trans. 2007;35:704–706. [PubMed]
39. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007;9:893–904. [PubMed]
40. Baciu PC, Suleiman EA, Deryugina EI, Strongin AY. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res. 2003;291:167–175. [PubMed]
41. Deryugina EI, Ratnikov BI, Strongin AY. Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer. 2003;104:533–541. [PubMed]
42. Barbolina MV, Stack MS. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol. 2008;19:24–33. [PMC free article] [PubMed]
43. Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM. Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A. 2004;101:6917–6922. [PubMed]
44. Ohkubo S, Miyadera K, Sugimoto Y, Matsuo K, Wierzba K, Yamada Y. Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library. Biochem Biophys Res Commun. 1999;266:308–313. [PubMed]
45. Sadlonova A, Novak Z, Johnson MR, et al. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 2005;7:R46–R59. [PMC free article] [PubMed]
46. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642–6650. [PubMed]